nLiven PR Human
Platelet Lysate
nLiven PR®
GMP-ready, pathogen-reduced human platelet lysate
As global regulatory expectations evolve, BioLife Solutions is there to meet the challenge. With validated pathogen-reduction technology, nLiven PR® established the gold standard for performance and quality of irradiated pooled human platelet lysate (hPL).
- Utilizes E-Beam irradiation for pathogen reduction, meeting EU Pharmacopoeia standards.
- A Biodefined composition that reduces lot-to-lot variability compared to traditional platelet lysate preparations.
- Contains high concentrations of growth factors and cytokines, promoting cell growth and proliferation.
- Manufactured under a certified ISO 9001:2015 Quality Management System and is FDA registered and inspected since 2011.
- Manufactured in accordance with cGMP standards.
- Manufactured from large donor pool lot sizes.
- Available in 100 mL and 500 mL sizes.
- Typically used at 2%-10% concentrations.
- FDA Master File, Japan PMDA Certificate of Suitability.
- Improved cell growth and performance: nLiven PR provides a biodefined growth supplement that supports a wide range of cell types, including MSCs, T-cells, NK cells, and endothelial cells, and promotes improved cell quality, especially in CAR-T applications.
- Reduced risk of contamination: The pathogen-reduction step in the manufacturing process of nLiven PR minimizes the residual risk of pathogens/viruses in the final product.
- Reduced lot-to-lot variability: The biodefined composition of nLiven PR helps to reduce inconsistencies between batches, leading to more predictable and robust cell manufacturing.
- Lower cost of goods (COGs): Studies suggest that nLiven PR can support reduced supplemental cytokine addition, potentially leading to lower costs in scaled GMP manufacturing processes.
- Increased T-cell memory phenotypes: Research indicates that culturing T-cells with nLiven PR can lead to a higher population of central memory T cells, which are important for therapy persistence in vivo.
- Reduced donor-to-donor variability: Using nLiven PR supplemented media has been shown to result in lower variability in cell yield and central memory phenotypes compared to other options like AB serum, leading to more consistent culture conditions.
- Clinical trial use: nLiven PR is currently utilized in multiple clinical studies globally, demonstrating its effectiveness in real-world applications.
Please download nLiven PR resources here:
Frequently asked questions
nLiven PR contains a pathogen-reduction step in the manufacturing process to minimize the residual risk of pathogens/viruses contained in the final product.
nLiven PR is pathogen reduced by electron-beam irradiation.
Yes, viral inactivation studies have been completed.
BioLife Solutions has data supporting performance up to at least 17 months from date of manufacture at -20°C storage.
Yes. nLiven PR is used in multiple clinical studies across the globe.
Ex vivo expansion of cells such as MSCs, ASCs, T cells, etc. Please connect with us to learn which BioLife Solutions hPL is right for your application.
Yes. We are ISO9001:2015 certified.
